Friday, November 22, 2024

CND Life Sciences Partners with Soleo Health to Broaden the Awareness and Availability

CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, is pleased to announce its strategic collaboration with Soleo Health®, a leading national provider of complex specialty pharmacy services, to educate neuromuscular specialists and other neurologists on CND’s novel Syn-One Test® and its intraepidermal nerve fiber density assay called Small-Fiber Dx™.

Also Read: Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from

CND’s Syn-One Test uniquely detects the abnormal, pathological form of the alpha-synuclein protein by analyzing small skin biopsies collected from patients in a neurologist’s office. This misfolded protein is the hallmark of a family of diseases called synucleinopathies, which includes Parkinson’s disease, dementia with Lewy bodies, and pure autonomic failure. Diagnosing these diseases, particularly when early signs and symptoms emerge, can be very challenging. With a high level of sensitivity and specificity, the Syn-One Test provides pathological proof of misfolded alpha-synuclein within a patient’s skin biopsy sample, allowing the clinician to make a diagnosis with greater confidence before establishing a treatment plan.

“We are in an era of medicine where precision diagnostics have become increasingly crucial to optimize patient care,” said Rick Morello, CND Life Sciences‘ Chief Executive Officer. “We are quite pleased to work with Soleo Health as a key partner to help CND educate neurologists who could benefit most from incorporating Syn-One and other cutaneous neurodiagnostics into their practice.”

There are many sub-specialties within neurology that could benefit from the Syn-One Test, including physicians who treat movement disorders, cognitive disorders, sleep disorders, and neuromuscular disorders. Within the neuromuscular field are physicians who care for patients with autonomic neuropathies. These patients experience symptoms of abnormal control of blood pressure, heart rate, sweating, digestion, and bladder processes. The accumulation of misfolded alpha-synuclein is one of the pathological pathways that can lead to damaged autonomic nerves and autonomic dysfunction. Syn-One is the first commercial cutaneous test that can help physicians determine if the underlying cause of the autonomic neuropathy is a synucleinopathy (like Parkinson’s disease) or that it may be due to a different medical condition. CND’s collaboration with Soleo Health is intended to facilitate neurologists’ access to Syn-One’s unique diagnostic technology.

Subscribe Now

    Hot Topics